Al­ways chas­ing the newest sci­ence, Schond Green­way joins MindMed; Mi­rati fills key va­can­cy with ex-Are­na fi­nance chief

From cell ther­a­py to pre­ci­sion med­i­cine, Schond Green­way has hopped from one bur­geon­ing re­search area to the next through­out his ca­reer. Now he’s head­ing off to an­oth­er: psy­che­del­ic ther­a­py.

MindMed tapped Green­way as CFO on Mon­day, as CEO Robert Bar­row guides the com­pa­ny through what he called “an ex­cit­ing point in our growth.” The New York-based psy­che­delics com­pa­ny was the sec­ond to ever go pub­lic on an Amer­i­can ex­change, be­hind Com­pass Path­ways. And this year, Bar­row’s lin­ing up “nu­mer­ous near-term mile­stones ahead across our pipeline.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER